LEXX Lexaria Bioscience Corp.
Nasdaq · SEC CIK 1348362 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 65 since 2021-07-21, latest 2026-03-18
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| BUNKA CHRISTOPHER | Dir | — | — |
Transactions 19
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-18 | 2026-03-17 | LEXX | BUNKA CHRISTOPHER | Dir | G - Gift | $0.00 | -100.0K | 273.5K | -27% | $0 | |
| MI | 2025-07-30 | 2025-07-29+ | LEXX | BUNKA CHRISTOPHER | Dir | P - Purchase | $0.9157 | +27.5K | 281.9K | +11% | +$25.2K |
| 2025-07-30 | 2025-07-29 | LEXX | DOCHERTY JOHN MARTIN | Pres, CSO, Dir | P - Purchase | $0.93 | +5,376 | 5,376 | New | +$5,000 | |
| 2025-07-30 | 2025-07-29 | LEXX | McKechnie William Edward | Dir | P - Purchase | $0.91 | +5,000 | 18.2K | +38% | +$4,550 | |
| 2025-07-30 | 2025-07-29 | LEXX | CHRISTOPHER RICHARD | CEO, Dir | P - Purchase | $0.91 | +15.0K | 65.0K | +30% | +$13.7K | |
| 2025-07-30 | 2025-07-29 | LEXX | Carle Vanessa | Sec | P - Purchase | $0.91 | +750 | 750 | New | +$682.50 | |
| 2025-01-10 | 2025-01-07 | LEXX | BUNKA CHRISTOPHER | Dir | A - Grant | $0.00 | +100.0K | 373.5K | +37% | $0 | |
| M | 2024-12-03 | 2024-12-02+ | LEXX | CHRISTOPHER RICHARD | CEO | P - Purchase | $2.36 | +50.0K | 22.8K | New | +$118.2K |
| 2024-08-13 | 2024-08-12 | LEXX | TURKEL CATHERINE C. | Dir | P - Purchase | $3.13 | +1,600 | 3,100 | +107% | +$5,008 | |
| 2024-08-01 | 2024-07-31 | LEXX | Carle Vanessa | Sec | S - Sale | $4.00 | -2,567 | 0 | -100% | -$10.3K | |
| D | 2024-05-15 | 2024-05-14 | LEXX | Carle Vanessa | Sec | M - OptEx | $1.15 | +2,500 | 2,567 | +3,731% | +$2,875 |
| 2023-02-27 | 2023-02-09 | LEXX | TURKEL CATHERINE C. | Dir | P - Purchase | $2.84 | +1,500 | 1,500 | New | +$4,260 | |
| MAI | 2022-10-18 | 2022-10-12+ | LEXX | BUNKA CHRISTOPHER | CEO, Dir | P - Purchase | $2.04 | +38.5K | 254.4K | +18% | +$78.4K |
| 2022-10-18 | 2022-10-14 | LEXX | Downey Gregory | CFO | A - Grant | $2.09 | +121 | 1,954 | +7% | +$252.89 | |
| A | 2022-10-18 | 2022-10-14 | LEXX | Downey Gregory | CFO | P - Purchase | $2.09 | +121 | 1,954 | +7% | +$252.89 |
| MI | 2022-10-13 | 2022-10-12+ | LEXX | BUNKA CHRISTOPHER | CEO, Dir | A - Grant | $2.04 | +38.5K | 254.4K | +18% | +$78.4K |
| 2022-05-25 | 2022-05-24 | LEXX | REESE ALBERT L JR | Dir | A - Grant | $1.96 | +5,000 | 10.9K | +85% | +$9,800 | |
| 2022-05-24 | 2022-05-20 | LEXX | REESE ALBERT L JR | Dir | A - Grant | $2.01 | +1,799 | 5,917 | +44% | +$3,616 | |
| M | 2022-05-19 | 2022-05-18+ | LEXX | REESE ALBERT L JR | Dir | A - Grant | $2.01 | +3,201 | 2,617 | New | +$6,434 |
Purchase Sale Sale after option exercise All abbreviations